Clinical trials: Mantle Cell Lymphoma (MCL)
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphomas, Immunocytomas
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no…
- Conditions
- Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas, Mantle-Cell Lymphomas
- Trial name
- MAINTAIN (NCT00877214)
- Testing
- Rituximab, Rituximab / observation
- Where
- Germany
- Volunteers
- 1,272 people
- Sponsor
- Jurgen Barth
Lymphoma
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more cancer cells.
- Trial name
- NCT00053768
- Testing
- filgrastim, EPOCH regimen, cyclophosphamide
- Where
- 175 sites in Germany, Switzerland
- Volunteers
- 392 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Mantle Cell Lymphoma
Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma
Patients with mantle cell lymphoma have a grave prognosis. They usually have an initial response to therapy, however progress early in the course of the disease and have very poor survival.
- Trial name
- NCT00586755
- Testing
- Intensive Induction-BMT
- Volunteers
- 48 people
- Sponsor
- Duke University
Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
This trial will enroll patients with relapsed/refractory DLBCL and MCL, with the opportunity to receive single-agent glofitamab as early as the second-line.
- Trial name
- NCT07748364
- Testing
- Glofitamab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Joshua Brody
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Anemia, B-Cell Prolymphocytic Leukemia
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma…
- Conditions
- Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma
- Trial name
- NCT03010358
- Testing
- Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alexey Danilov, MD
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- PROSECO (NCT04858568)
- Where
- 9 sites in United Kingdom
- Volunteers
- 592 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Mantle Cell Lymphoma
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
This study aims to preliminarily explore the efficacy and safety of the combination of Obinutuzumab and Zanubrutinib plus Lenalidomide (ZGR) followed by a short cycle of cytarabine and Obinutuzumab in the induction treatment of…
- Trial name
- ZGR (NCT06504199)
- Testing
- Obinutuzumab, Zanubrutinib, Lenalidomide
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy.
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT04205409
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ofatumumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and dexamethasone alternating with ofatumumab in combination with cytarabine and methotrexate…
- Conditions
- Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma
- Trial name
- NCT01527149
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Mantle Cell Lymphoma
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating…
- Trial name
- NCT04626791
- Testing
- Acalabrutinib, Bortezomib, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Academic and Community Cancer Research United
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
- Trial name
- NCT01693614
- Testing
- Buparlisib
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Neoplasms
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
This trial will evaluate the safety and efficacy of post-transplant Cy and sirolimus following reduced intensity allogeneic SCT.
- Trial name
- NCT01244906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northside Hospital, Inc.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Lapatinib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00352443
- Testing
- everolimus, lapatinib ditosylate
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- SWOG Cancer Research Network
Lymphoid Malignancies
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics…
- Trial name
- NCT01705847
- Testing
- GS-9820
- Where
- 4 sites in Netherlands
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or…
- Conditions
- Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- R/R (NCT04419389)
- Testing
- APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aprea Therapeutics
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Double Cord Versus Haploidentical (BMT CTN 1101)
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can be used for HCT.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma, Follicular Lymphoma
- Trial name
- NCT01597778
- Testing
- Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant
- Where
- 39 sites in United States
- Volunteers
- 368 people
- Sponsor
- Medical College of Wisconsin
CD20-positive B-cell Non-Hodgkin Lymphoma
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
The purpose of this study is to identify if, and at what dose, ibrutinib may be administered with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and to document responses of this combination in…
- Trial name
- NCT01569750
- Testing
- Part 1, Cohort 1, Part 1, Cohort 2, Part 1, Cohort 3
- Where
- 7 sites in United States, France
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC